BT PHARMA’s strategy is to remain focussed on the internal development of therapeutic vaccines for treatment of diseases provoked by HPV such as cervical cancer. Our proprietary vector platforms, (CyaA) and have however the potential to be used for a broad range of other vaccine applications and as a result are available for evaluation with your target antigens.
In addition to our vector platforms, our programme (Tumour Associated Antigen Vaccine) has rendered two immuno-competent cancer vaccine candidates available for evaluation, co-development and licensing. Jointly they address a majority of cancers of the oesophagus, stomach, liver, pancreas, colon, rectum and lung. The market potential addressed by these candidate vaccine components is in excess of 1 billion Euros each and more if combined.
Collaborations
Partnerships opportunities
How to start and finish a technology or product evaluation project within 12 months?
1 week for establishment of non-disclosure agreement
2 weeks for exchange of confidential information exchange and advice
3 weeks for drafting of personalized Evaluation Agreement
4 weeks for reaching to terms.
5 months to 10 months to complete the study, transmit data, results and reports.
For further information, please contact business@btpharma.com
Current partnerships
BT PHARMA currently has three industrial partnerships that cover either the use our CyaA technology or PepTel system.
BT PHARMA has a strategic alliance with the Institut Pasteur in the field of immuno-therapeutics and vaccines. This agreement provides the company with privileged access to the Institute's genomics, bio-informatics and analytic technology platforms as well as to novel patented technologies related to immuno-therapy and vaccines.
BT PHARMA has also entered into a number of academic collaborations with research academy teams at the Institut Pasteur in Paris, the IPBS, University of Toulouse / CNRS, the University of Ghent, , Belgium, the Ludwig Institut for Cancer Research, Belgium, Maximillian University of Munich, Germany and the University of Prague, Czech Republic. These collaborations are designed to further characterise our proprietary technology platforms and the immune responses that they induce as well as to the use and development of advanced methods for screening vaccine candidates.